Core Insights - Kenvue Inc. (NYSE:KVUE) is recognized as one of the 10 best stocks under $20 to buy according to hedge funds, with Barclays raising its price target from $18 to $19 while maintaining an Equalweight rating [1] - The company has shown strong performance in classic consumer health categories, particularly in Self Care and Essential Health, but needs to adopt a different strategy for its beauty segment focused on premiumization and innovation [2] - Canaccord Genuity also raised its price target for Kenvue from $17 to $18, maintaining a Hold rating, following the company's Q4 and full-year 2025 results [3] Financial Performance - Kenvue's Q4 sales increased by 3.2% year-over-year, surpassing the Street estimate of 0.4%, with organic sales rising by 1.2% compared to the same period last year [4] - All segments of Kenvue reported growth in Q4, and the adjusted EPS was $0.27, exceeding the Street estimate of $0.22 [4] - Kenvue is a global consumer health company with well-known brands including Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol [4]

Company Overview - Kenvue Inc. is a global consumer health company headquartered in Summit, New Jersey, with a market cap of approximately $34.8 billion, categorizing it as a large-cap company [1] - The company focuses on everyday health and personal care products, maintaining a diverse portfolio that addresses a wide range of daily health needs [1] Product Portfolio - Kenvue offers over-the-counter treatments for various health issues, including cough, cold, allergies, pain relief, and digestive health, alongside skincare, haircare, oral care, and baby care products [2] - The company features well-known brands such as Tylenol, Benadryl, Zyrtec, Neutrogena, Aveeno, Listerine, BAND-AID, and Johnson's, which have built consumer trust over decades [2] Stock Performance - Kenvue's stock is currently trading 28.7% below its 52-week high of $25.17 reached in May 2025, with a modest increase of 3.7% over the past three months [3] - Over the last 52 weeks, Kenvue's shares have declined by 24.9%, although there has been a 4.1% gain year-to-date (YTD) [6] - In comparison, the State Street Consumer Staples Select Sector SPDR ETF (XLP) has increased by 3.7% over the same 52-week period and surged by 10.4% in 2026 [6] Technical Indicators - Since mid-November 2025, Kenvue's shares have mostly traded above their 50-day moving average of $17.85, indicating short-term stability [7] - However, the stock has consistently remained below its 200-day moving average of $18.75 since August 2025, suggesting a lack of investor confidence in the stock's long-term trajectory [7] Financial Performance - In the latest earnings release on February 17, 2025, Kenvue reported Q4 revenue of $3.78 billion, reflecting a year-over-year increase of 3.2% and surpassing Street expectations of $3.71 billion [8]

Core Viewpoint - UBS and Citigroup have raised their price targets for Kenvue Inc. following strong fourth-quarter results, indicating positive market sentiment towards the company's performance and growth potential [1][2]. Group 1: Price Target Adjustments - UBS increased Kenvue's price target to $19 from $17 while maintaining a Neutral rating after the company reported better-than-expected fourth-quarter results [1]. - Canaccord Genuity also raised its price target to $18 from $17, keeping a Hold rating, highlighting that Kenvue beat expectations on both revenue and earnings [1]. - Citigroup raised its price target to $20 from $18, also maintaining a Neutral rating, following Kenvue's reported revenue of $3.78 billion for Q4 2025, which exceeded the consensus estimate of $3.69 billion [2]. Group 2: Company Performance - Kenvue's fourth-quarter results showed year-over-year growth in all three business segments for the first time since Q2 2023, aided by favorable foreign exchange conditions [1]. - CEO Kirk Perry noted that the company ended 2025 with stronger performance due to disciplined execution of strategic priorities and easier year-over-year comparisons [2]. - Kenvue Inc. was founded in 2022 as a spin-off from Johnson & Johnson and operates as a major global consumer health firm with a portfolio that includes well-known brands like Tylenol, Neutrogena, Band-Aid, Listerine, and Aveeno [3].

Group 1: Chevron - Chevron offers a reliable dividend yield of 4% and has increased its dividend for 37 consecutive years, making it a strong candidate for passive income [4][6] - The company has outlined a plan to grow free cash flow (FCF) and earnings per share by at least 10% when Brent crude oil prices are at $70, with a breakeven point at $50 per barrel [5] - Chevron's solid balance sheet provides a cushion during downturns, allowing it to maintain its dividend even if oil prices fall below $50 [5] Group 2: Kimberly Clark - Kimberly Clark, known for brands like Kleenex and Huggies, is currently priced below $100 a share, which is a 12-year low, presenting a potential buying opportunity [9] - The company announced the acquisition of Kenvue, aiming for billions in annual cost synergies and expecting to grow earnings in the second year post-acquisition [9][10] - Kimberly Clark has a 5.2% dividend yield and a forward price-to-earnings ratio of 13.1, positioning it as a strong value stock for passive income [12]

Core Viewpoint - Consumer staples stocks, particularly those that are currently undervalued, present a significant buying opportunity for value investors, especially in light of their underperformance compared to the broader market [1][2]. Group 1: Procter & Gamble (P&G) - P&G experienced a challenging 2025, with a stock value decline of 14.5%, reaching a near three-year low [4]. - The company reported a 1% decline in sales volume and flat organic sales growth, leading to a 5% drop in diluted net earnings per share (EPS) [5]. - P&G has adjusted its fiscal 2026 diluted net EPS growth forecast to a range of 1% to 6%, down from a previous estimate of 3% to 9% [5]. - The company is under new leadership and aims to enhance its value proposition by focusing on volume growth rather than price increases [8]. - P&G boasts a strong dividend yield of 2.9% and has increased its dividend for 69 consecutive years, making it an attractive option for income investors [9][11]. Group 2: Kimberly-Clark - Kimberly-Clark reported a modest 3.2% growth in adjusted EPS and flat adjusted operating profit, with a 1.7% increase in organic sales [12]. - The company is in a downturn but plans to acquire Kenvue to diversify its product offerings, which is expected to enhance its market position [13]. - Kimberly-Clark anticipates achieving $2.1 billion in annual cost synergies from the acquisition within three years [15]. - The company has a dividend yield of 5% and has increased its dividend for 54 consecutive years, making it appealing for value investors [17][19]. Group 3: Comparative Analysis - P&G is considered a higher quality company with a strong brand portfolio and better diversification, while Kimberly-Clark offers a cheaper valuation and higher yield, making it a potential turnaround play [20]. - Both companies are currently facing growth challenges due to a slowdown in consumer spending but continue to generate substantial free cash flow and earnings to support their dividends [20]. - A balanced investment strategy could involve a 50/50 split between both stocks, yielding an average of 4% [21].

Core Viewpoint - Kimberly-Clark Corporation and Kenvue Inc. have received overwhelming shareholder approval for Kimberly-Clark's acquisition of Kenvue, marking a significant step towards creating a global health and wellness leader [1][2]. Group 1: Transaction Details - The acquisition transaction is expected to close in the second half of 2026, pending regulatory approvals and other customary closing conditions [3]. - Approximately 96% of shares present at Kimberly-Clark's Special Meeting voted in favor of the share issuance related to the transaction [2]. - At Kenvue's Special Meeting, about 99% of shares voted to adopt the merger agreement, representing approximately 77% of all outstanding shares [2]. Group 2: Company Statements - Kimberly-Clark's CEO, Mike Hsu, expressed gratitude to shareholders for their support and emphasized the potential to raise care standards for billions globally while generating significant shareholder value [2]. - Kenvue's CEO, Kirk Perry, highlighted the growth opportunities for the combined company and the potential to accelerate innovation and expand access to trusted brands [2]. Group 3: Company Backgrounds - Kimberly-Clark operates in over 175 countries with a portfolio of brands that hold No. 1 or No. 2 market share positions in approximately 70 countries, focusing on sustainable practices [4]. - Kenvue is recognized as the world's largest pure-play consumer health company by revenue, with a heritage of over a century and a portfolio of well-known brands [5].

Core Viewpoint - Kimberly-Clark Corporation is actively pursuing a nearly $49 billion acquisition of Kenvue, which is seen as a bold move given Kenvue's stock has significantly decreased since its public offering [2] Group 1: Company Overview - Kimberly-Clark Corporation manufactures personal care products, including diapers, wipes, feminine and incontinence care products, and household paper goods [2] - The company's notable brands include Huggies, Kotex, Depend, Kleenex, Scott, and Cottonelle [2] Group 2: Acquisition Details - The planned acquisition of Kenvue includes its well-known over-the-counter products such as Tylenol, Band-Aids, and Aveeno [2] - Concerns have been raised regarding the potential risks associated with Kenvue, particularly related to Tylenol and its alleged links to autism, as mentioned by the Secretary of Health and Human Services [2] Group 3: Market Perspective - Jim Cramer highlighted that the weakness in Kimberly-Clark's stock may be more related to Kenvue's issues rather than Kimberly-Clark itself [1] - The company currently offers a 5% yield and is trading at 13 times earnings, which Cramer finds intriguing [1]

Group 1: M&A Market Overview - Global mergers and acquisitions (M&A) surged in 2025, reaching approximately $4.5 trillion, which is about 50% above 2024 levels and the second-largest annual total on record [1] - The deal boom in 2025 was characterized by a high value of cash transactions, with 68 deals worth at least $10 billion, marking the highest number of megadeals in recent years [2][3] Group 2: Notable Megadeals - The largest deal involved a bidding war between Paramount and Netflix for Warner Bros. Discovery, with Netflix's equity value at $72 billion and Paramount's revised bid at $108.4 billion [4] - The second-largest deal was an $88.26 billion rail merger between Union Pacific and Norfolk Southern, announced in July [5] - Electronic Arts (EA) shareholders approved a $55 billion sale to a consortium led by Saudi Arabia's Public Investment Fund, marking a record-setting leveraged buyout in the gaming industry [5] - Kimberly-Clark's acquisition of Kenvue, valued at $40 billion, was the fourth largest deal, involving a consumer health company known for various well-known brands [6] - The fifth largest deal was the $40 billion acquisition of Aligned Data Centers by a consortium led by BlackRock's Global Infrastructure Partners, marking the largest data center transaction on record [7]

Core Insights - Not every stock requires a high-growth narrative to outperform; consistency in execution is key for long-term success [1] - In 2025, certain companies are achieving significant year-to-date gains while providing reliable income, characterized by strong management and resilience across market cycles [1] Dividend Kings - The focus is on identifying Dividend Kings, which are companies that have increased their dividends for over 50 consecutive years, emphasizing long-term value and near-term momentum based on 2025 performance [2] - The selection process involved using Barchart's Stock Screener with specific filters to identify stocks with strong year-to-date performance [3][4] Johnson & Johnson (JNJ) - Johnson & Johnson is a major player in the healthcare sector, known for a wide range of pharmaceutical products and consumer brands [5] - The company reported a year-over-year sales increase of 7% to $24 billion and a net income growth of over 90% to $5.2 billion [6] - JNJ's stock has risen over 45% year-to-date, making it the top-performing Dividend King in 2025 [6]

Core Viewpoint - Kimberly-Clark Corporation (NASDAQ:KMB) is recognized as a strong investment opportunity, particularly following its better-than-expected third quarter earnings and plans to acquire Kenvue, enhancing its consumer health presence [2][3]. Group 1: Company Performance - Kimberly-Clark has recently upgraded its rating to Buy from Hold, with a price target set at $120, indicating a positive outlook despite recent stock lagging [2]. - The company reported better-than-expected earnings for the third quarter, which has contributed to the stronger outlook from analysts [2]. Group 2: Acquisition and Market Position - Kimberly-Clark plans to acquire Kenvue, a company that focuses on consumer health and owns several well-known brands, with the deal expected to be completed in the second half of next year [2][3]. - Both Kimberly-Clark and Kenvue operate in resilient product categories, making KMB an attractive long-term investment option [3]. Group 3: Revenue Generation - The majority of Kimberly-Clark's revenue is generated through direct sales to various channels, including retailers, distributors, and online platforms [4]. - The company serves a diverse global customer base, including supermarkets, big-box stores, drugstores, and institutional buyers across multiple sectors [4].